Buchumschlag

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151-20...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Raghu, Ganesh (VerfasserIn) , Hamblin, Mark J. (VerfasserIn) , Brown, A. Whitney (VerfasserIn) , Golden, Jeffrey A. (VerfasserIn) , Ho, Lawrence A. (VerfasserIn) , Wijsenbeek, Marlies S. (VerfasserIn) , Vasakova, Martina (VerfasserIn) , Pesci, Alberto (VerfasserIn) , Antin-Ozerkis, Danielle E. (VerfasserIn) , Meyer, Keith C. (VerfasserIn) , Kreuter, Michael (VerfasserIn) , Burgess, Tracy (VerfasserIn) , Kamath, Nikhil (VerfasserIn) , Donaldson, Francis (VerfasserIn) , Richeldi, Luca (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 21 May 2022
In: Respiratory research
Year: 2022, Jahrgang: 23, Pages: 1-12
ISSN:1465-993X
DOI:10.1186/s12931-022-02047-0
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-022-02047-0
Volltext
Verfasserangaben:Ganesh Raghu, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E. Antin-Ozerkis, Keith C. Meyer, Michael Kreuter, Tracy Burgess, Nikhil Kamath, Francis Donaldson and Luca Richeldi
Beschreibung
Zusammenfassung:Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151-202 study. Interim (76-week) data from the open-label extension (OLE) demonstrated sustained safety and efficacy with rhPTX-2 treatment. Here, we present the entire long-term OLE safety and efficacy data to 128 weeks.
Beschreibung:Gesehen am 01.07.2022
Beschreibung:Online Resource
ISSN:1465-993X
DOI:10.1186/s12931-022-02047-0

Ähnliche Einträge